Hydrochloric Acid → (R)-2-hydroxy-1-(4-(2-(2-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)butan-1-one hydrochloride

HRID 2062179노트

반응식

HRID 2062179 반응식
[OH:1][C@H:2]([CH2:28][CH3:29])[C:3]([N:5]1[CH2:10][CH2:9][N:8]([C:11]2[C:20]3[C:15](=[CH:16][CH:17]=[CH:18][CH:19]=3)[N:14]=[C:13]([C:21]3[CH:26]=[CH:25][CH:24]=[CH:23][C:22]=3[OH:27])[N:12]=2)[CH2:7][CH2:6]1)=[O:4].[ClH:30].CCOCC>C(Cl)Cl>[ClH:30].[OH:1][C@H:2]([CH2:28][CH3:29])[C:3]([N:5]1[CH2:10][CH2:9][N:8]([C:11]2[C:20]3[C:15](=[CH:16][CH:17]=[CH:18][CH:19]=3)[N:14]=[C:13]([C:21]3[CH:26]=[CH:25][CH:24]=[CH:23][C:22]=3[OH:27])[N:12]=2)[CH2:7][CH2:6]1)=[O:4]

참가 물질

5

실험 절차

To a solution of (R)-2-hydroxy-1-(4-(2-(2-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)butan-1-one (280 mg, 0.71 mmol) in CH2Cl2 under an N2 atmosphere was added a 2 M HCl solution in ether (0.355 mL, 0.71 mmol), followed by the addition of ether which resulted in the formation of precipitate which was stirred for an hour and then filtered and dried to afford (R)-2-hydroxy-1-(4-(2-(2-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)butan-1-one hydrochloride (272 mg, 90%). LC/MS: m/z 393.1 (M+H)+ at 2.23 min (10%-99% CH3CN (0.035% TFA)/H2O (0.05% TFA)). 1H NMR (400 MHz, DMSO-d6) δ 8.27 (dd, J=7.9, 1.6 Hz, 1H), 8.19 (d, J=8.4 Hz, 1H), 7.96 (m, 2H), 7.65 (m, 1H), 7.48 (m, 1H), 7.04 (m, 2H), 4.26 (dd, J=7.7, 4.8 Hz, 1H), 4.03 (m, 4H), 3.79 (m, 5H), 1.65 (m, 1H), 1.50 (m, 1H), 0.90 (t, J=7.4 Hz, 3H).

후처리

  1. customresulted in the formation of precipitate which
  2. filtrationfiltered
  3. customdried

출처 및 근거

ORD 기록
ord-5511ee2fd0b5453a97cc77b39df04f45
출처 데이터셋
uspto-grants-2012_10
특허 번호
US08283354B2

반응 노트

불러오는 중…